Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

The effects of vitamin C in combination with tyrosine kinase inhibitor on tumor size, tumor markers, inflammatory factor levels, quality of life, duration of resistance, progression‐free survival, and overall survival time were evaluated. This trial is a low risk treatment, and has developed the appropriate safety measures and contingency plans to ensure patients' safety in the whole process. Patients will be followed up after the end of the trial, and follow‐up observations will be performed every month during the first year. Followed every 3 months in the second year for 3 years.